Florent Peyraud1,2, Sophie Cousin1,2, Antoine Italiano3,4. 1. Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. 2. Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. 3. Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. a.italiano@bordeaux.unicancer.fr. 4. Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.
Abstract
PURPOSE OF REVIEW: Colony-stimulating factor 1 receptor (CSF-1R) and its ligands, CSF-1 and interleukin 34 (IL-34), regulate the function and survival of tumor-associated macrophages, which are involved in tumorigenesis and in the suppression of antitumor immunity. Moreover, the CSF-1R/CSF-1 axis has been implicated in the pathogenesis of pigmented villonodular synovitis (PVNS), a benign tumor of the synovium. As advanced or metastatic malignant solid tumors and relapsed/refractory PVNS remain unresolved therapeutic problems, new approaches are needed to improve the outcome of patients with these conditions. RECENT FINDINGS: In solid tumors, targeting CSF-1R via either small molecules or antibodies has shown interesting results in vitro but limited antitumor activity in vivo. Concerning PVNS, clinical trials assessing CSF-1R inhibitors have revealed promising initial outcomes. Blocking CSF-1/CSF-1R signaling represents a promising immunotherapy approach and several new potential combination therapies for future clinical testing.
PURPOSE OF REVIEW: Colony-stimulating factor 1 receptor (CSF-1R) and its ligands, CSF-1 and interleukin 34 (IL-34), regulate the function and survival of tumor-associated macrophages, which are involved in tumorigenesis and in the suppression of antitumor immunity. Moreover, the CSF-1R/CSF-1 axis has been implicated in the pathogenesis of pigmented villonodular synovitis (PVNS), a benign tumor of the synovium. As advanced or metastatic malignant solid tumors and relapsed/refractory PVNS remain unresolved therapeutic problems, new approaches are needed to improve the outcome of patients with these conditions. RECENT FINDINGS: In solid tumors, targeting CSF-1R via either small molecules or antibodies has shown interesting results in vitro but limited antitumor activity in vivo. Concerning PVNS, clinical trials assessing CSF-1R inhibitors have revealed promising initial outcomes. Blocking CSF-1/CSF-1R signaling represents a promising immunotherapy approach and several new potential combination therapies for future clinical testing.
Authors: David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens Journal: Cancer Discov Date: 2011-06-01 Impact factor: 39.397
Authors: Parag P Patwardhan; Oliver Surriga; Michael J Beckman; Elisa de Stanchina; Ronald P Dematteo; William D Tap; Gary K Schwartz Journal: Clin Cancer Res Date: 2014-04-09 Impact factor: 12.531
Authors: Robert B West; Brian P Rubin; Melinda A Miller; Subbaya Subramanian; Gulsah Kaygusuz; Kelli Montgomery; Shirley Zhu; Robert J Marinelli; Alessandro De Luca; Erinn Downs-Kelly; John R Goldblum; Christopher L Corless; Patrick O Brown; C Blake Gilks; Torsten O Nielsen; David Huntsman; Matt van de Rijn Journal: Proc Natl Acad Sci U S A Date: 2006-01-06 Impact factor: 11.205
Authors: Stephen L Shiao; Brian Ruffell; David G DeNardo; Bruce A Faddegon; Catherine C Park; Lisa M Coussens Journal: Cancer Immunol Res Date: 2015-02-25 Impact factor: 11.151
Authors: Teresa S Kim; Michael J Cavnar; Noah A Cohen; Eric C Sorenson; Jonathan B Greer; Adrian M Seifert; Megan H Crawley; Benjamin L Green; Rachel Popow; Nagavarakishore Pillarsetty; Darren R Veach; Anson T Ku; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Shan Zeng; Ronald P Dematteo Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Rulla M Tamimi; Joan S Brugge; Matthew L Freedman; Alexander Miron; J Dirk Iglehart; Graham A Colditz; Susan E Hankinson Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: T Conor McKee; Jeffrey A Belair; Keenan Sobol; Scot A Brown; John Abraham; William Morrison Journal: Skeletal Radiol Date: 2020-01-07 Impact factor: 2.199
Authors: Catherine A Foss; Alvaro A Ordonez; Ravi Naik; Deepankar Das; Andrew Hall; Yunkou Wu; Robert F Dannals; Sanjay K Jain; Martin G Pomper; Andrew G Horti Journal: Eur J Nucl Med Mol Imaging Date: 2022-06-17 Impact factor: 10.057
Authors: Silvia Mola; Giulia Pinton; Marco Erreni; Marco Corazzari; Marco De Andrea; Ambra A Grolla; Veronica Martini; Laura Moro; Chiara Porta Journal: Int J Mol Sci Date: 2021-04-22 Impact factor: 5.923
Authors: Tomohiro Fujiwara; Mohamed A Yakoub; Andrew Chandler; Alexander B Christ; Guangli Yang; Ouathek Ouerfelli; Vinagolu K Rajasekhar; Aki Yoshida; Hiroya Kondo; Toshiaki Hata; Hiroshi Tazawa; Yildirim Dogan; Malcolm A S Moore; Toshiyoshi Fujiwara; Toshifumi Ozaki; Ed Purdue; John H Healey Journal: Mol Cancer Ther Date: 2021-06-04 Impact factor: 6.009